Search

Your search keyword '"Prodan, Andrei"' showing total 52 results
Start Over Author "Prodan, Andrei"
52 results on '"Prodan, Andrei"'

51. Faecal microbiota transplantation halts progression of human new-onset type 1 diabetes in a randomised controlled trial

Author

Willem M. de Vos, Lorenzo Piemonti, Andrei Prodan, Nordin M J Hanssen, Frank Stam, Suat Simsek, Bartjan Potter van Loon, Jacques J. Bergman, Evgeni Levin, Victor E. A. Gerdes, Martin Diekman, Catherina Brouwer, Bart O. Roep, Gaby Duinkerken, Sultan Imangaliyev, Valeria Sordi, Antoinette Joosten, Guido J. Bakker, Joost B. L. Hoekstra, Ilias Attaye, Daniël H. van Raalte, Arianne C. van Bon, Martin Gerding, Han Levels, Frits Holleman, Aeilko H. Zwinderman, Cees Rustemeijer, Roel P.L.M. Hoogma, Tanja Nikolic, Elena Rampanelli, Max Nieuwdorp, Bernadette S. de Bakker, Silvia Pellegrini, Pieter F. de Groot, Sytze van Dam, Graduate School, ACS - Diabetes & metabolism, ACS - Amsterdam Cardiovascular Sciences, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, Pathology, Vascular Medicine, ACS - Atherosclerosis & ischemic syndromes, Experimental Vascular Medicine, Medical Biology, ARD - Amsterdam Reproduction and Development, Epidemiology and Data Science, APH - Methodology, Gastroenterology and Hepatology, ACS - Heart failure & arrhythmias, Internal medicine, Amsterdam Gastroenterology Endocrinology Metabolism, Gastroenterology and hepatology, Surgery, AGEM - Endocrinology, metabolism and nutrition, de Groot, Pieter, Nicolic, Tanja, Pellegrini, Silvia, Sordi, Valeria, Imangaliyev, Sultan, Rampanelli, Elena, Hanssen, Nordin, Attaye, Ilia, Bakker, Guido, Duinkerken, Gaby, Joosten, Annemarie, Prodan, Andrei, Levin, Evgeni, Levels, Han, Potter van Loon, Bartjan, van Bon, Arianne, Brouwer, Catherina, van Dam, Sytze, Simsek, Suat, van Raalte, Daniel, Stam, Frank, Gerdes, Victor, Hoogma, Roel, Diekman, Martin, Gerding, Martin, Rustemeijer, Cee, de Bakker, Bernadette, Hoekstra, Joost, Zwinderman, Aeilko, Bergman, Jacque, Holleman, Frit, Piemonti, Lorenzo, De Vos, Willem, Roep, Bart, and Nieuwdorp, Max

Subjects
0301 basic medicine, Adult, Male, medicine.medical_specialty, Adolescent, Duodenum, medicine.medical_treatment, T cell, 030209 endocrinology & metabolism, medicine.disease_cause, Gastroenterology, Transplantation, Autologous, Microbiology, Autoimmunity, 03 medical and health sciences, chemistry.chemical_compound, Young Adult, 0302 clinical medicine, Microbiologie, Internal medicine, Diabetes mellitus, Insulin-Secreting Cells, medicine, Humans, Type 1 diabetes, C-Peptide, C-peptide, business.industry, Insulin, BacGen, Fecal Microbiota Transplantation, medicine.disease, Pathophysiology, Gastrointestinal Microbiome, 030104 developmental biology, medicine.anatomical_structure, Diabetes Mellitus, Type 1, chemistry, diabetes mellitus, Female, Beta cell, business
Abstract

ObjectiveType 1 diabetes (T1D) is characterised by islet autoimmunity and beta cell destruction. A gut microbiota–immunological interplay is involved in the pathophysiology of T1D. We studied microbiota-mediated effects on disease progression in patients with type 1 diabetes using faecal microbiota transplantation (FMT).DesignPatients with recent-onset (ResultsStimulated C peptide levels were significantly preserved in the autologous FMT group (n=10 subjects) compared with healthy donor FMT group (n=10 subjects) at 12 months. Small intestinal Prevotella was inversely related to residual beta cell function (r=−0.55, p=0.02), whereas plasma metabolites 1-arachidonoyl-GPC and 1-myristoyl-2-arachidonoyl-GPC levels linearly correlated with residual beta cell preservation (rho=0.56, p=0.01 and rho=0.46, p=0.042, respectively). Finally, baseline CD4 +CXCR3+T cell counts, levels of small intestinal Desulfovibrio piger and CCL22 and CCL5 gene expression in duodenal biopsies predicted preserved beta cell function following FMT irrespective of donor characteristics.ConclusionFMT halts decline in endogenous insulin production in recently diagnosed patients with T1D in 12 months after disease onset. Several microbiota-derived plasma metabolites and bacterial strains were linked to preserved residual beta cell function. This study provides insight into the role of the intestinal gut microbiome in T1D.Trial registration numberNTR3697.

Published
2020
Full Text
View/download PDF

52. Duodenal Anaerobutyricum soehngenii infusion stimulates GLP-1 production, ameliorates glycaemic control and beneficially shapes the duodenal transcriptome in metabolic syndrome subjects: a randomised double-blind placebo-controlled cross-over study.

Author

Koopen A, Witjes J, Wortelboer K, Majait S, Prodan A, Levin E, Herrema H, Winkelmeijer M, Aalvink S, Bergman JJGHM, Havik S, Hartmann B, Levels H, Bergh PO, van Son J, Balvers M, Bastos DM, Stroes E, Groen AK, Henricsson M, Kemper EM, Holst J, Strauch CM, Hazen SL, Bäckhed F, De Vos WM, Nieuwdorp M, and Rampanelli E

Subjects
Blood Glucose metabolism, Blood Glucose Self-Monitoring, Clostridiales, Cross-Over Studies, Double-Blind Method, Glucagon-Like Peptide 1 metabolism, Glycemic Control, Humans, Insulin metabolism, Male, Transcriptome, Diabetes Mellitus, Type 2 drug therapy, Insulin Resistance, Metabolic Syndrome genetics
Abstract

Objective: Although gut dysbiosis is increasingly recognised as a pathophysiological component of metabolic syndrome (MetS), the role and mode of action of specific gut microbes in metabolic health remain elusive. Previously, we identified the commensal butyrogenic Anaerobutyricum soehngenii to be associated with improved insulin sensitivity in subjects with MetS. In this proof-of-concept study, we investigated the potential therapeutic effects of A. soehngenii L2-7 on systemic metabolic responses and duodenal transcriptome profiles in individuals with MetS., Design: In this randomised double-blind placebo-controlled cross-over study, 12 male subjects with MetS received duodenal infusions of A. soehngenii / placebo and underwent duodenal biopsies, mixed meal tests (6 hours postinfusion) and 24-hour continuous glucose monitoring., Results: A. soehngenii treatment provoked a markedly increased postprandial excursion of the insulinotropic hormone glucagon-like peptide 1 (GLP-1) and an elevation of plasma secondary bile acids, which were positively associated with GLP-1 levels. Moreover, A. soehngenii treatment robustly shaped the duodenal expression of 73 genes, with the highest fold induction in the expression of regenerating islet-protein 1B ( REG1B )-encoding gene. Strikingly, duodenal REG1B expression positively correlated with GLP-1 levels and negatively correlated with peripheral glucose variability, which was significantly diminished in the 24 hours following A. soehngenii intake. Mechanistically, Reg1B expression is induced upon sensing butyrate or bacterial peptidoglycan. Importantly, A. soehngenii duodenal administration was safe and well tolerated., Conclusions: A single dose of A. soehngenii improves peripheral glycaemic control within 24 hours; it specifically stimulates intestinal GLP-1 production and REG1B expression. Further studies are needed to delineate the specific pathways involved in REG1B induction and function in insulin sensitivity., Trial Registration Number: NTR-NL6630., Competing Interests: Competing interests: MN is in the scientific board of Kaleido Biosciences, Boston USA. WMDV is founder and in the board of A-mansia, Belgium. FB is in the scientific board of Metabogen AB, Sweden. MN and WMDV are founders and Scientific Advisory Board members of Caelus Pharmaceuticals, the Netherlands. SLH is a paid consultant for P&G and coinventor on pending and issued patents held by the Cleveland Clinic, and is eligible for receiving payments for inventions or discoveries related to cardiovascular diagnostics or therapeutics from Cleveland HeartLab, Quest Diagnostics and P&G., (© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results